VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
HOWL
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HOWLWerewolf Therapeutics, Inc.
$0.35$17M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksHOWLQuarterly Financials

Werewolf Therapeutics, Inc. (HOWL) Quarterly Financials

120+ quarters historyFree accessUpdated daily

Werewolf Therapeutics, Inc. (HOWL) quarterly income statement — complete revenue, gross profit & net income history

HOWL Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricQ1'26Q4'25Q3'25Q2'25Q1'25Q4'24Q3'24Q2'24Q1'24Q4'23Q3'23Q2'23
Sales/Revenue00000001.14M742K1.5M5.9M8.08M
Revenue Growth %----100%-100%-100%-100%-85.86%-83.38%-79.39%18.65%94.82%
Cost of Goods Sold398K00406K426K00454K464K460K445K0
COGS % of Revenue-------39.72%62.53%30.65%7.55%-
Gross Profit-398K00-406K-426K00689K278K1.04M5.45M8.08M
Gross Margin %-------60.28%37.47%69.35%92.45%100%
Gross Profit Growth %6.57%---158.93%-253.24%-100%-100%-91.47%-93.77%118.04%27.92%182.98%
Operating Expenses8.57M9.42M15.73M17.14M17.57M20.35M17.12M19.65M17.44M14M14.7M14.15M
OpEx % of Revenue-------1719.07%2350.4%932.91%249.33%175.08%
Selling, General & Admin5.09M2.48M4.09M4.4M4.87M4.62M4.6M4.38M4.53M4.35M4.31M4.57M
SG&A % of Revenue-------383.03%610.78%290.07%73.09%56.49%
Research & Development8.18M6.93M11.63M13.14M13.12M15.73M12.53M15.27M12.91M9.65M10.84M9.58M
R&D % of Revenue-------1336.05%1739.62%642.84%183.79%118.59%
Other Operating Expenses-1000K00-406K-426K00000-445K0
Operating Income-8.97M-9.42M-15.73M-17.54M-17.99M-20.35M-17.12M-18.96M-17.16M-12.96M-9.25M-6.07M
Operating Margin %--------1658.79%-2312.94%-863.56%-156.88%-75.08%
Operating Income Growth %50.16%53.72%8.16%7.48%-4.83%-56.98%-85.1%-212.51%-40.41%1.65%26.22%59.48%
EBITDA-8.57M-9.02M-15.32M-17.14M-17.57M-19.91M-16.67M-18.51M-16.7M-12.5M-8.81M-5.63M
EBITDA Margin %--------1619.07%-2250.4%-832.91%-149.33%-69.71%
EBITDA Growth %51.22%54.7%8.07%7.4%-5.19%-59.22%-89.3%-228.53%-41.53%2.04%25.57%61.91%
D&A (Non-Cash Add-back)398K400K402K406K426K442K454K454K464K460K445K434K
EBIT-8.97M-7.01M-15.73M-16.68M-16.83M-19.13M-15.43M-16.11M-15.19M-10.76M-9.25M-4.14M
Net Interest Income-935K-805K-644K-451K-266K42K354K651K970K965K971K994K
Interest Income433K564K0850K997K1.31M1.6M1.79M1.97M2.2M1.87M1.95M
Interest Expense1.37M1.37M644K1.3M1.26M1.27M1.24M1.14M1M1.24M900K955K
Other Income/Expense-4.57M1.04M-644K-440K-98K-52K451K1.71M969K959K966K969K
Pretax Income-13.53M-8.38M-16.37M-17.98M-18.09M-20.4M-16.67M-17.25M-16.19M-12M-8.29M-5.1M
Pretax Margin %--------1509.1%-2182.35%-799.67%-140.5%-63.09%
Income Tax000000000000
Effective Tax Rate %0%0%0%0%0%0%0%0%0%0%0%0%
Net Income-13.53M-8.38M-16.37M-17.98M-18.09M-20.4M-16.67M-17.25M-16.19M-12M-8.29M-5.1M
Net Margin %--------1509.1%-2182.35%-799.67%-140.5%-63.09%
Net Income Growth %25.19%58.92%1.82%-4.25%-11.71%-69.96%-101.24%-238.35%-35.14%-0.61%30.63%65.07%
Net Income (Continuing)-13.53M-8.38M-16.37M-17.98M-18.09M-20.4M-16.67M-17.25M-16.19M-12M-8.29M-5.1M
Discontinued Operations000000000000
Minority Interest000000000000
EPS (Diluted)-0.28-0.17-0.36-0.40-0.40-0.46-0.38-0.40-0.39-0.33-0.23-0.14
EPS Growth %30%63.04%5.26%0%-2.56%-39.39%-65.22%-185.71%-14.71%5.71%39.47%73.08%
EPS (Basic)-0.28-0.17-0.36-0.40-0.40-0.46-0.38-0.40-0.39-0.33-0.23-0.14
Diluted Shares Outstanding49.39M46.81M45.8M44.98M44.83M44.48M43.7M43.52M41.61M36.57M35.65M35.56M
Basic Shares Outstanding48.6M46.02M45.47M44.98M44.83M44.48M43.7M43.52M41.61M36.57M35.65M35.56M
Dividend Payout Ratio------------